HealthTech Startups That Failed: Innovation vs. Regulation
HealthTech has the longest startup timeline (7-10 years to profitability) and an 85% failure rate. The 2020-2023 telehealth bubble (Babylon, Olive, Pear, Cerebral, Forward) wiped out $8B+ as reimbursement, clinical evidence and CAC all failed simultaneously.
75+
Documented
$43B
Capital raised
85%†
Industry est.
5.2 years
Closed lifespan
† Industry-wide estimate from external sources (BLS, CB Insights, PitchBook) — different denominator from the corpus counts. See methodology.
HealthTech Startups That Failed: what our corpus actually shows
IdeaProof Startup Failure Database · 1,000 verified true-failure events · data as of August 2026
Across these 75 cases, the dominant failure cause is fraud & technology that never worked (1% of shutdowns), followed by one-time dna test had no recurring revenue; drug-discovery pivot failed; 2023 data breach destroyed trust (1%). Together they account for 2% of documented failures in this slice, representing $27.0B of capital raised and lost.
Cite as: IdeaProof Startup Failure Database (2026), "HealthTech Startups" slice, n=75. Licensed CC BY-NC 4.0.
Market Context (2026)
Telehealth utilization fell from 32% (2020 peak) to ~8% of outpatient visits by 2024. Asynchronous primary-care models could not match in-person reimbursement rates.
Payer scrutiny (UnitedHealth, Cigna, Elevance) on virtual-first care, mental health prescribing (Cerebral) and weight-loss telehealth (Ro, Hims) tightened in 2024-25.
AI clinical co-pilots (Abridge, Suki, Nabla) are the new bright spot — but only with EHR distribution deals (Epic / Oracle Health).
Failure Reasons in This Industry
Capital Destruction Timeline
Theranos shut down after fraud exposure
$700M raised, $9B peak
Pear Therapeutics fails reimbursement, prescription digital therapeutics collapse
$400M+ raised
Babylon Health delists, files for administration in UK
$4.2B → ~0
Olive AI shuts down after $850M raise
$850M lost
Forward Health, Cerebral cut services and layoffs
$500M+ raised each
Several Series C digital therapeutics quietly wind down post-IRA pricing
$1B+ category
Common Failure Patterns
Regulatory Complexity
FDA approval, HIPAA compliance, and insurance reimbursement create 3-5 year delays that burn through startup capital.
Long Sales Cycles
Selling to hospitals and health systems takes 12-18 months per deal. Startups run out of money waiting for procurement approvals.
Science Risk
From Theranos to numerous biotech failures — the underlying science doesn't always work as promised, and failure is binary.
Survivor Playbook vs Failure Pattern
What survivors do
- ✓Start with regulatory strategy — it should inform your product roadmap, not be an afterthought
- ✓Target self-pay or employer-funded segments to avoid insurance reimbursement complexity
- ✓Build clinical evidence early — peer-reviewed studies dramatically accelerate sales
- ✓Partner with health systems for distribution rather than trying to sell directly
What failures did
- ✗Regulatory Complexity — FDA approval, HIPAA compliance, and insurance reimbursement create 3-5 year delays that burn through startup capital.
- ✗Long Sales Cycles — Selling to hospitals and health systems takes 12-18 months per deal. Startups run out of money waiting for procurement approvals.
- ✗Science Risk — From Theranos to numerous biotech failures — the underlying science doesn't always work as promised, and failure is binary.
Regulatory & Macro Landscape
United States
FDA 510(k) and De Novo + HIPAA/HITECH compliance; DEA telehealth prescribing rules
CMS
Telehealth parity rollbacks post-PHE; new RPM billing audits
European Union
MDR + EU AI Act high-risk classification for medical devices
United Kingdom
NICE evidence requirements and NHS procurement cycles >18 months
Investor & Operator Lessons
- 1Reimbursement code is the moat; without a CPT/HCPCS path the TAM is theoretical.
- 2Clinical evidence is a 3-5 year project — bake it into Series A planning.
- 3Health system pilots ≠ revenue; budget 18 months from pilot to first PO.
- 4Vertically integrated care (own clinicians + payer contracts) outperforms pure-software plays.
Failed Startups (75)
Juul Labs
Regulatory Crackdown & Youth Vaping · A $38B e-cigarette company that hooked teenagers on nicotine faced total regulat…
$15B
2015–2024
Clover Health
SPAC Fraud Allegations & Unsustainable Losses · Chamath Palihapitiya's SPAC empire promised to democratize investing. Clover Hea…
$1.3B+
2014–2024
Bright Health
Catastrophic underwriting losses; forced to sell core insurance business to survive · Disrupting insurance with a tech UX doesn't help if your actuarial models are wr…
$2.4B
2016–2023
Oscar Health
Healthcare costs outpaced tech savings · Oscar raised $1.6B to make health insurance user-friendly with a consumer tech a…
$1.6B
2012–2025
Cano Health
Chapter 11 after acquisition-led expansion left it with $1B+ debt and negative cash flow · Roll-up healthcare growth funded by debt is not "value-based care" — it is lever…
$1.5B+ debt & equity
2009–2024
23andMe
One-time DNA test had no recurring revenue; drug-discovery pivot failed; 2023 data breach destroyed trust · A consumer product without recurring revenue is not a business. 23andMe sold a o…
$1.4B
2006–2025
Intarcia Therapeutics
Regulatory failure, capital exhaustion, manufacturing issues · In regulated industries, manufacturing quality and alignment with regulatory exp…
$1.4B
1997–2020
Babylon Health
US value-based care expansion buried the AI-triage story · Buying a US value-based-care book of business is a very expensive way to prove y…
$1.2B+
2013–2023
Theranos
Fraud & Technology That Never Worked · Silicon Valley 'fake it till you make it' collapses on contact with regulated he…
$945M
2003–2018
Olive AI
Overpromised RPA as 'AI', under-delivered ROI to hospitals · Selling AI to hospitals requires proven ROI per workflow, not a $4B narrative. O…
$902M
2012–2023
SmileDirectClub
Regulatory fights, dentist opposition, unit-economics collapse post-IPO · Regulated categories don't reward 'move fast and break things'. SDC's IPO peak w…
$900M+ (incl. 2019 IPO)
2014–2023
Zymergen
Premature scaling, product-market fit issues · Biology is complex and not easily scalable like software; prematurely scaling wi…
$900.0M
2013–2021
Olive (Health AI)
Integration Complexity · Healthcare AI automation faces unique integration challenges that make scaling n…
$856M
2012–2023
Practice Fusion
DOJ Kickback Fraud & Failed Business Model · Free EHR software monetized by pharmaceutical advertising created a fatal confli…
$150M
2005–2020
CureFit (Cult.fit)
Over-Diversification & COVID Impact · CureFit tried to be everything — gym, food, mental health, primary care — at onc…
$620M
2016–2023
iTeos Therapeutics
GSK terminated TIGIT partnership after negative Phase 2 lung cancer data · Big-pharma partnerships aren't insurance. GSK, Merck and Roche have all walked a…
$600M+ (public)
2011–2025
Proteus Digital Health
Adoption Failure & Complexity · Ingestible sensors in pills to track medication compliance is technically fascin…
$500M
2001–2020
Outcome Health
Fraud & Overbilling · Fabricating advertising metrics to justify $500M in investment is fraud.…
$500M
2006–2023
MicroPort
Mismatch of low-cost and high-tech · Medical device innovation requires significant R&D, regulatory expertise, and cl…
$500M
1998–2024
Cue Health
Post-Covid demand collapse, FDA authorization issues, cash-out failure · Pandemic-boom hardware companies rarely survive normalisation. Cue's at-home mol…
$480M+ (incl. 2021 IPO)
2010–2024
Health IQ
Fraud — Fabricated Metrics & False Claims · Insurance is a heavily regulated industry where fabricated data doesn't just mis…
$130M
2013–2023
Areteia Therapeutics
Phase 3 asthma studies terminated for insufficient efficacy · A $425M startup bet on a single molecule is a coin-flip. Diversify the shots on …
$425M
2022–2025
Pear Therapeutics
Payer Reimbursement Failure · FDA-approved digital therapeutics don't matter if insurance companies refuse to …
$418M
2013–2023
Sichuan Kelun-Biotech
Capital inefficiency, weak pipeline, market saturation · Biotech startups need 10x differentiation, not incremental improvement, especial…
$400M
2016–2024
Cerebral
Overprescription Scandal & DOJ Investigation · Telehealth ADHD prescribing at scale attracted DEA scrutiny and a DOJ investigat…
$300M
2020–2024
Weidong Cloud
Strategic incoherence, poor product-market fit · Attempting a 'boil the ocean' strategy by targeting too many customer segments s…
$300M
2012–2024
Color Health
Post-Pandemic Revenue Collapse · Pivoting from genomics to COVID testing generated temporary revenue but left no …
$278M
2013–2024
Wheel Health
Post-COVID Telehealth Collapse · Wheel built telehealth infrastructure for the COVID era. When the pandemic ended…
$216M
2018–2024
Inspirna
Failed to raise Phase 3 funding; folded before pivotal trial · If you can't fund the Phase 3 you designed, the design was wrong. Downsize the t…
$210M
2014–2025
Fapon Biotech
Failed to commercialize products · Developing biosimilars in competitive markets often leads to commoditization and…
$200M
2001–2024
Yiyao
Unsustainable unit economics, strategic misalignment · Healthcare marketplaces require structural advantages beyond product, as even si…
$200M
2015–2024
Mythic Therapeutics
Bridge round failed; single ADC clinical trial terminated for funding reasons · A single-asset biotech's Series C is the last cheque. If Phase 1/2 data isn't re…
$180M
2018–2025
Trusted Health
Post-Pandemic Demand Collapse · Travel nurse demand skyrocketed during COVID but crashed when the pandemic ended…
$175M
2017–2024
IO Biotech
Filed for Chapter 7 bankruptcy · A single pivotal trial narrowly missing statistical significance can be as fatal…
$170M
2014–2026
Mindstrong
Unvalidated claims, regulatory issues, poor reimbursement · In healthcare, rigorous clinical validation and a sustainable reimbursement mode…
$160M
2014–2024
Nurx
Regulatory Issues & Unsustainable Unit Economics · Telehealth for birth control prescriptions seemed like a perfect digital health …
$150M+
2015–2023
Xiaohe
Regulatory crackdown, competition, unit economics · Regulatory risk is existential in heavily regulated industries like healthcare; …
$150M
2020–2023
Elvie
Unsustainable hardware unit economics, narrow LTV · Hardware startups must achieve sustainable unit economics and a strong LTV:CAC r…
$150M
2013–2025
Jianke
Competitive asphyxiation in crowded market · Pure-play startups cannot compete with tech giants in winner-take-most markets w…
$150M
2011–2024
Bridgetech China
Regulatory & go-to-market execution · In China's healthcare B2B market, institutional trust and government relations o…
$140M
2021–2025
DrKoop.com
Unsustainable burn, fraudulent revenue, no product-market fit · Celebrity endorsement is a temporary asset; sustainable business models require …
$130M
1997–2001
Sensei Biotherapeutics
Dropped sole clinical program to conserve remaining cash before shell status · If you're a $30M-market-cap public biotech that just failed a readout, don't bur…
$130M+ (public)
1999–2025
Jiyan AI
Regulatory whiplash, slow sales, scope creep · B2B sales in regulated markets like healthcare require immense capital, long cyc…
$120M
2021–2024
Nido Biosciences
Drug failed Phase II clinical trial · Even well-capitalized biotechs backed by reputable venture studios can be forced…
$109 million
2020–2026
uBiome
Insurance Fraud & FBI Raid · Billing insurance for medically unnecessary microbiome tests is healthcare fraud…
$105M
2012–2019
Spotlight Therapeutics
Technical failure, capital inefficiency, market timing · Personalized neoantigen prediction is still largely inaccurate, requiring empiri…
$100M
2017–2025
Meatable
Commercialization chasm, deeptech complexity, insufficient runway · Deeptech startups, especially in capital-intensive areas like cultivated meat, m…
$100M
2018–2025
Portea Medical
Unit Economics & Scaling Challenges · Home healthcare in India sounds perfect on paper but Portea discovered that mana…
$75M
2013–2023
Mfine Singapore (Wind-Down)
Post-COVID Demand Collapse · Singapore-headquartered telehealth Mfine raised US$60M during COVID then heavily…
$60M
2017–2023
Ribbon Health
API-only data infrastructure absorbed into vertical analytics leader · Being 'the data layer' is a great narrative and a hard business. If a bigger ana…
$59M
2016–2025
Nine Square Therapeutics
Liquidity crisis, funding standstill · Even well-funded platform biotechs targeting scientifically validated but histor…
$55 million
2020–2026
54gene
Strategic Confusion & Founder Departure · Africa's most-funded genomics startup, 54gene, shut down after founder departed …
$45M
2019–2023
Spotlight Bio\USA
Algorithmic predictions lacked experimental validation · Computational predictions in biotech require rigorous experimental validation an…
$40M
2018–2025
Base Therapeutics
Product/tech failure, capital inefficiency · AI drug discovery requires deep wet-lab validation, regulatory navigation, and c…
$34.5M
2021–2025
Call9
Unsustainable business model, rapid expansion · A novel business model requiring significant behavioral change in a regulated in…
$34M
2015–2019
Withings (Nokia Acquisition Crisis)
Nokia Write-Down & Failed Integration · Paris connected-health pioneer Withings was acquired by Nokia for €170M in 2016,…
$30M
2008–2017
Miga Health
Virtual specialty care model couldn't clear payer reimbursement thresholds · Virtual specialty clinics live or die on payer contracts. If your CPT-code strat…
$26M
2021–2025
HomeHero
Misunderstood healthcare economics & regulations · Healthcare marketplaces require defensible supply and a deep understanding of re…
$23M
2013–2017
Kevala
Sub-scale point solution absorbed by broader senior-care platform · Vertical workforce SaaS with <$5M ARR gets acquired, not IPO'd. Design your cap …
$18M
2018–2025
Joon Care
Consolidation into larger virtual mental-health platform via acqui-hire · If the category consolidates before you find defensible unit economics, taking t…
$13M
2019–2025
Onco
Sub-scale patient acquisition led to a quiet strategic acquisition by Apollo Hospitals · In Indian health-tech, the exit is the largest hospital chain, not the IPO. Buil…
$7M
2018–2024
Kismet Health
Acquired by Kooth for its telehealth platform, ending standalone operations · A specialized telehealth toolset can be worth more inside a larger buyer than as…
$6M
2020–2025
Fermata
Ran out of capital before commercial viability · Deep-tech biotech startups have non-negotiable, high capital requirements that m…
$5.0M
2019–2024
Tandem App
Lack of differentiation and market demand · Even with a pervasive problem, solutions must offer strong differentiation and i…
$5.0M
2018–2022
JiviAI
Ran out of runway before proving clinical adoption of a medical LLM · Selling AI into regulated healthcare requires 24+ months and hospital champions.…
$4M
2023–2026
Raw Gains
Inexperienced founders, strategic and operational missteps · Founders must possess or acquire essential strategic planning and operational ma…
$3.5M
2017–2021
BusyMind
Lack of focus, market differentiation · In crowded markets, focused differentiation and sustainable growth loops are cri…
$3.0M
2017–2022
Nintee
Premature scaling, poor unit economics · Indian health-tech requires a 'Trojan Horse' business model, starting with low-v…
$2M
2023–2024
Botnim
Poor market fit, logistical data challenges · Thoroughly validate market fit and address data scalability challenges before si…
$1.5M
2016–2019
Forward Health
Forward Health, a venture-backed primary care startup that raised over $650 million to build AI-powered 'CarePod' health kiosks, abruptly shut down all clinics and its app in late 2024, with the fallo · In healthcare, sudden business pivots and shutdowns carry a duty of care to pati…
$657m
2016–2025
Mojocare
Broken unit economics, misread customer psychology · Stigma-driven markets require immense trust-building beyond just privacy; custom…
Unknown
2020–2023
Kopely
Over-reliance on external development partners · External development can lead to loss of control, impacting product quality, ite…
Unknown
2020–2022
Lipella Pharmaceuticals
Bankruptcy, inability to develop drug · Positive clinical trial data does not guarantee survival; without continued acce…
Under $20m
2017–2026
Lipocine Inc.
Phase 3 trial failed primary endpoint · Repeated regulatory delays on a single lead drug can trigger a slow erosion of s…
$150m+
–2026
Moleculin Biotech Inc.
Weak pipeline, funding contraction · Single-asset oncology biotechs remain acutely vulnerable to any negative trial r…
$100m+
2020–2025
Frequently Asked Questions
Why do healthcare startups fail?
Healthcare startups fail due to: (1) regulatory barriers (FDA, HIPAA) that add years and millions in compliance costs, (2) long sales cycles when selling to hospitals/payers, (3) science/technology risk (the product may not work), and (4) the complexity of healthcare workflows that resist disruption.
What is the most famous healthcare startup failure?
Theranos ($700M raised, $9B peak valuation) is the most infamous — Elizabeth Holmes claimed to revolutionize blood testing but the technology never worked. She was convicted of fraud and sentenced to 11+ years in prison.
Is digital health still a good market?
Yes, but capital requirements are high and timelines are long. The most successful digital health companies (Veeva, Doximity) focused on B2B/enterprise sales rather than consumer health apps. AI-assisted diagnostics and clinical workflow automation show the most promise.
How long does it take for a healthcare startup to succeed?
Healthcare startups typically take 7-10 years to achieve profitability, compared to 3-5 years for software startups. FDA approval alone can take 2-7 years depending on the classification.
Explore Other Industries
Enterprise SaaS & Software Startups That Failed
144 cases fail rate · verified dataset
E-commerce Startups That Failed
80% fail rate · 3.8 years
Fintech Startups That Failed
75% fail rate · 4.2 years
Social Media & Communication Startups That Failed
84 cases fail rate · verified dataset
EV & Automotive Startups That Failed
90% fail rate · 5.5 years
EdTech Startups That Failed
70% fail rate · 4.8 years
Food Delivery Startups That Failed
80% fail rate · 3.5 years
Consumer Hardware & Devices Startups That Failed
61 cases fail rate · verified dataset
Media, Streaming & Entertainment Startups That Failed
40 cases fail rate · verified dataset
Don't become the next case study.
Validate your idea against 75+ healthcare failures and 1000+ across all sectors — in 60 seconds.